The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Open accessAbstract
Amyloid plaques and neurofibrillary tangles (NFTs) are the pathological hallmarks of Alzheimer disease (AD). There is controversy regarding the use of current diagnostic criteria for AD and whether amyloid plaques and NFTs contribute to cognitive impairment. Because AD is specific to humans, rigorous and comprehensiveclinicopathologic studies are necessary to test and refine hypotheses of AD diagnosis and pathogenesis. Neither the clinical nor the pathological aspects of AD evolve in a linear manner, but thepredictable sequence of AD pathology allows for stage-based correlations with cognitive deterioration. We discuss subsets of patients with clinical dementia who lack amyloid plaques and NFTs and, conversely, whether individuals without antemortem cognitive impairment can harbor severe AD-type pathological findings at autopsy. There are many medical, technical, and anatomical challenges to clinicopathologic studies in AD. For example, at least two thirds of persons older than 80 years have non-AD brain diseases that can effect on cognitive function. We argue that existing data strongly support the hypothesis that both amyloid plaques and NFTs contribute to cognitive impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“leading to dysfunction and loss of synapses and eventual neuronal death1,2.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by an accumulation of senile plaques (SP) [composed mostly of fibrillary amyloid beta-peptide (Aβ) and dystrophic neurites] and neurofibrillary tangles (NFT) [composed of hyperphosphorylated tau protein] in the brain”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Clinically, AD is characterized by several features, notably a progressive cognitive decline involving loss of memory and higher executive functioning1.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Evaluation of AD status was conducted by the AD Center Neuropathology and Clinical Cores using guidelines set forth by the National Institute on Aging Reagan Institute that included evaluation of neurofibrillary tangles and neuritic senile plaques [36–38].”
From Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts (2016) · cites this paper as [37]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Indeed, the first pathological insults to neurons in AD and aMCI occur at pre- and post-synaptic membranes1,3.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
Experimental — accuracy not yet measured
In the citing paper
“Indeed, this is precisely the observation reported by one of the largest autopsy series to date (142) and is well supported by AD biomarker studies (143-145).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“It is expected that many persons die with brains that exhibit AD neuropathologic change in the preclinical phase of AD; indeed, data support the modeled expectations (44, 142).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“It is important to emphasize that, among thousands of cases from dozens of CPC studies worldwide, there never has been a report of a thoroughly documented individual with truly “end-stage” neocortical NFT pathology who lacked antemortem cognitive impairment proximal to death (142, 151).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“In a review of 11 different studies comprising 555 subjects without dementia, a total of 12 brains were assessed as Braak stage V (2.2%); 3 were assessed as Braak stage VI (0.5%) (142).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“However, not all Braak stage VI brains were the same; there was significant variation in NFT burden in these cases (142, 151).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“In a review of 11 different studies comprising 555 subjects without dementia, a total of 12 brains were assessed as Braak stage V (2.2%); 3 were assessed as Braak stage VI (0.5%) (142).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“There have been many clinicopathological studies that have correlated amyloid plaques with cognitive deficits in AD, with an emerging picture that the strongest correlation exists in the earliest stages of the disease and this association greatly weakens as NFTs and neocortical degeneration become more widespread [9, 102, 103, 157, 160, 169].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Self-citationLOSS OF RECENT MEMORY AFTER BILATERAL HIPPOCAMPAL LESIONS
Scoville, W. B., & Milner, B. (1957) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.20.1.11 · Cited by 7,322
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Self-citationAlzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Research works printed but not linked: 1
- Centers for Disease Control and Prevention. Prevalence of stroke-United States, 2005. MMWR Morb Mortal Wkly Rep 2007;56:469–74
Cited by
Sorted by citations
Items 201–300 of 638
Epidemiological Approaches to Understanding the Link Between Type 2 Diabetes and Dementia
Sutherland, G. T., Lim, J., Srikanth, V. K., & Bruce, D. G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161194 · Cited by 58
Lista, S., Molinuevo, J. L., Cavedo, E., Rami, L., Amouyel, P., Teipel, S. J., Garaci, F., Toschi, N., Habert, M.-O., Blennow, K., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150202 · Cited by 53
Mandal, P. K., Roy, R. G., & Samkaria, A. (2022) · ACS Omega · doi:10.1021/acsomega.2c02760 · Cited by 56
Khundakar, A. A., & Thomas, A. J. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-148003 · Cited by 53
Guimond, M., & Gallo‐Payet, N. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00164 · Cited by 53
Cortical phase changes in Alzheimer's disease at 7T MRI: A novel imaging marker
van Rooden, S., Versluis, M. J., Liem, M. K., Milles, J., Maier, A. B., Oleksik, A. M., WEBB, A. G., van Buchem, M. A., & van der Grond, J. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.02.002 · Cited by 57
Expression of glia maturation factor in neuropathological lesions of Alzheimer's disease
Thangavel, R., Stolmeier, D. A., Yang, X., Anantharam, P., & Zaheer, A. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01232.x · Cited by 54
Barilar, J. O., Knezović, A., Grünblatt, E., Riederer, P., & Salkovic-Petrisic, M. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1323-y · Cited by 54
Alzheimer's Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy
Gammazza, A. M., Bavisotto, C. C., Barone, R., de Macario, E. C., & Macario, A. J. L. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160518141437 · Cited by 52
Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy
Zagórska, A., & Jaromin, A. (2020) · Molecules · doi:10.3390/molecules25153337 · Cited by 51
Projecting Burden of Dementia in Spain, 2010–2050: Impact of Modifying Risk Factors
Soto‐Gordoa, M., Arrospide, A., Moreno, F., Martínez‐Lage, P., Castilla‐Rodríguez, I., & Mar, J. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150233 · Cited by 50
“End-Stage” Neurofibrillary Tangle Pathology in Preclinical Alzheimer's Disease: Fact or Fiction?
Abner, E. L., Kryscio, R. J., Schmitt, F. A., SantaCruz, K. S., Jicha, G. A., Lin, Y., Neltner, J. M., Smith, C. D., Van Eldik, L. J., & Nelson, P. T. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101980 · Cited by 49
Self-citationTraumatic brain injury history and progression from mild cognitive impairment to Alzheimer disease.
LoBue, C., Woon, F. L. M., Rossetti, H. C., Hynan, L. S., Hart, J., & Cullum, C. M. (2018) · Neuropsychology · doi:10.1037/neu0000431 · Cited by 49
Qß Virus-like particle-based vaccine induces robust immunity and protects against tauopathy
Maphis, N. M., Peabody, J., Crossey, E., Jiang, S., Ahmad, F. A. J., Álvarez, M. J., Mansoor, S. K., Yaney, A., Yang, Y., Sillerud, L. O., et al. (2019) · npj Vaccines · doi:10.1038/s41541-019-0118-4 · Cited by 48
Nikolenko, V. N., Oganesyan, M. V., Rizaeva, N. A., Kudryashova, V. A., Nikitina, A. T., Pavliv, M. P., Анатольевна, Щ. М., Db, G., Bulygin, K. V., & Sinelnikov, M. Y. (2020) · Brain Sciences · doi:10.3390/brainsci10080502 · Cited by 48
Montine, T. J., Corrada, M. M., Kawas, C. H., Bukhari, S. A., White, L. R., Tian, L., & Cholerton, B. (2022) · Neurology · doi:10.1212/wnl.0000000000200832 · Cited by 51
Astara, K., Tsimpolis, A., Kalafatakis, K., Vavougios, G. D., Xiromerisiou, G., Dardiotis, E., Christodoulou, G. N., Samara, M. T., & Lappas, A. S. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111899 · Cited by 50
Gallardo-Fernández, M., Ortega, R. H., Cerezo, A. B., Troncoso, A. M., & García-Parrilla, M. C. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.110817 · Cited by 47
Farkas, S., Nagy, K., Palkovits, M., Kovács, G. G., Jia, Z., Donohue, S. R., Pike, V. W., Halldin, C., Máthé, D., Harkany, T., et al. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.11.004 · Cited by 47
Yadav, H., Jaldhi, Bhardwaj, R., Anamika, A., Bakshi, A., Gupta, S., & Maurya, S. K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122022 · Cited by 47
Neuroinflammation in Alzheimer's disease and beneficial action of luteolin
Delgado, A., Cholevas, C., & Theoharides, T. C. (2021) · BioFactors · doi:10.1002/biof.1714 · Cited by 48
DeBuc, D. C., Gaca-Wysocka, M., Grzybowski, A. E., & Kanclerz, P. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070996 · Cited by 47
Kok, F. K., van Leerdam, S., & de Lange, E. C. M. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-210607 · Cited by 46
Nelson, R. S., Abner, E. L., Jicha, G. A., Schmitt, F. A., Di, J., Wilcock, D. M., Barber, J. M., Eldik, L. J. V., Katsumata, Y., Fardo, D. W., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01576-z · Cited by 44
Self-citationMarongiu, R. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00242 · Cited by 47
Cognitive Dysfunction and Greater Visit‐to‐Visit Systolic Blood Pressure Variability
Epstein, N. U., Lane, K. A., Farlow, M. R., Risacher, S. L., Saykin, A. J., & Gao, S. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12542 · Cited by 44
Tremblay, C., François, A., Delay, C., Freland, L., Vandal, M., Bennett, D. A., & Calon, F. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw109 · Cited by 49
Akinyemi, R., Allan, L. M., Oakley, A. E., & Kalaria, R. N. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00717 · Cited by 43
Cerebral correlates of psychotic syndromes in neurodegenerative diseases
Jellinger, K. A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01311.x · Cited by 43
Abnormal kalirin signaling in neuropsychiatric disorders
Remmers, C. L., Sweet, R. A., & Penzes, P. (2013) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.12.006 · Cited by 45
Long, J. M., & Lahiri, D. K. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.12.043 · Cited by 44
Prion Disease Induces Alzheimer Disease—Like Neuropathologic Changes
Tousseyn, T., Bajsarowicz, K., Sanchez, H. C., Gheyara, A. L., Oehler, A., Geschwind, M., DeArmond, B., & DeArmond, S. J. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000228 · Cited by 45
Timmers, M., Tesseur, I. C., Bogert, J., Zetterberg, H., Blennow, K., Börjesson‐Hanson, A., Baquero, M., Boada, M., RANDOLPH, C. C., Tritsmans, L., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.03.016 · Cited by 43
Pontecorvo, M. J., Keene, C. D., Beach, T. G., Montine, T. J., Arora, A., Devous, M. D., Navitsky, M. A., Kennedy, I. A., Joshi, A. D., Lu, M., et al. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00653-x · Cited by 44
Effects of grape seed proanthocyanidin on Alzheimer's disease in vitro and in vivo
Lian, Q., Nie, Y., Zhang, X., Tan, B., Cao, H., Chen, W., Gao, W., Chen, J., Liang, Z., Lai, H., et al. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3530 · Cited by 41
Chronic Effects of Mild Neurotrauma: Putting the Cart Before the Horse?
Castellani, R. J., Perry, G., & Iverson, G. L. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000193 · Cited by 40
Avelar‐Pereira, B., Belloy, M. E., O'Hara, R. M., Hosseini, S. M. H., & Initiative, A. D. N. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01886-z · Cited by 42
Boche, D., & Nicoll, J. A. R. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12642 · Cited by 41
Lawn, T., Aman, Y., Rukavina, K., Sideris-Lampretsas, G., Howard, M. A., Ballard, C. G., Chaudhuri, К. R., & Malcangio, M. (2020) · Pain · doi:10.1097/j.pain.0000000000002111 · Cited by 41
Tau positron emission tomography in preclinical Alzheimer’s disease
Insel, P. S., Young, C. B., Aisen, P. S. S., Johnson, K. A., Sperling, R. A., Mormino, E. C., & Donohue, M. (2022) · Brain · doi:10.1093/brain/awac299 · Cited by 41
Stubbs, B., Thompson, T., Solmi, M., Vancampfort, D., Sergi, G., Luchini, C., & Veronese, N. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.05.016 · Cited by 39
Multiple Targets for the Management of Alzheimer’s Disease
Ahmad, S., Akhtar, S., Jamal, Q. M. S., Rizvi, S. M. D., Kamal, M. A., Khan, M. K., & Siddiqui, M. H. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666161003165855 · Cited by 39
Ma, W., Tao, Y., Wang, Y., & Peng, I. (2017) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(18)30005-0 · Cited by 38
Bhat, A. A., Moglad, E. H. O., Goyal, A., Afzal, M., Thapa, R., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., Ali, H., Gaur, A., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123056 · Cited by 38
Nascimento, C. F., Suemoto, C. K., Rodriguez, R. D., Alho, A. T. D. L., Leite, R. P., Farfel, J. M., Pasqualucci, C. A., Filho, W. J., & Grinberg, L. T. (2015) · Brain Pathology · doi:10.1111/bpa.12296 · Cited by 37
Brains from non-Alzheimer’s individuals containing amyloid deposits accelerate Aβ deposition in vivo
Duran-Aniotz, C. A., Morales, R., Moreno‐González, I., Hu, P. P., & Soto, C. A. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-76 · Cited by 40
Metaxas, A., Thygesen, C., Kempf, S. J., Anzalone, M., Vaitheeswaran, R., Petersen, S., Landau, A. M., Audrain, H., Teeling, J. L., Darvesh, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52357-5 · Cited by 39
Markovic, S. J., Fitzgerald, M., Peiffer, J. J., Scott, B. R., Rainey‐Smith, S. R., Sohrabi, H. R., & Brown, B. M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101322 · Cited by 37
Saiz‐Sánchez, D., de la Rosa‐Prieto, C., Úbeda‐Bañón, I., & Martı́nez-Marcos, A. (2013) · The Anatomical Record · doi:10.1002/ar.22750 · Cited by 37
Philipson, O., Lord, A., Lalowski, M. M., Soliymani, R., Baumann, M., Thyberg, J., Bogdanović, N., Olofsson, T., Tjernberg, L. O., Ingelsson, M., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.022 · Cited by 40
Nelson, P. T., Kukull, W. A., & Frosch, M. P. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181d8db07 · Cited by 37
Self-citationDysfunction of G Protein-Coupled Receptor Kinases in Alzheimer's Disease
Suo, W. Z., & Li, L. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.154 · Cited by 37
Braak stage and trajectory of cognitive decline in noncognitively impaired elders
Mufson, E. J., Malek‐Ahmadi, M. H., Snyder, N. L., Ausdemore, J., Chen, K., & Perez, S. E. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.003 · Cited by 38
Defective Autophagy and Mitophagy in Alzheimer’s Disease: Mechanisms and Translational Implications
Chen, J., He, H., Ye, Q., Feng, F., Wang, W., Gu, Y., Han, R., & Xie, C. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02487-7 · Cited by 37
Kloske, C. M., Dugan, A. J., Weekman, E. M., Winder, Z., Patel, E., Nelson, P. T., Fardo, D. W., & Wilcock, D. M. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab085 · Cited by 37
Self-citationThe chaperone Clusterin in neurodegeneration−friend or foe?
Yuste‐Checa, P., Bracher, A., & Hartl, F. U. (2022) · BioEssays · doi:10.1002/bies.202100287 · Cited by 37
Deformation based feature selection for Computer Aided Diagnosis of Alzheimer’s Disease
Savio, A. M., & Graña, M. (2012) · Expert Systems with Applications · doi:10.1016/j.eswa.2012.09.009 · Cited by 36
The importance of cognitive ageing for understanding dementia
Singh‐Manoux, A., & Mika Kivimaki, B. (2010) · AGE · doi:10.1007/s11357-010-9147-7 · Cited by 39
Acosta, D. M., Mancinelli, C. D., Bracken, C., & Eliezer, D. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101442 · Cited by 36
Altered Parietal-Motor Connections in Alzheimer's Disease Patients
Bonnı̀, S., Lupo, F., Gerfo, E. L., Martorana, A., Perri, R., Caltagirone, C., & Koch, G. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121144 · Cited by 39
Yi, L., Wu, T., Luo, W., Zhou, W., & Wu, J. (2014) · Neural Regeneration Research · doi:10.4103/1673-5374.125332 · Cited by 35
Does compensatory neural activity survive old-old age?
Daffner, K. R., Sun, X., Tarbi, E. C., Rentz, D. M., Holcomb, P. J., & Riis, J. L. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.08.006 · Cited by 35
Staging Neurodegenerative Disorders: Structural, Regional, Biomarker, and Functional Progressions
Archer, T., Kostrzewa, R. M., Beninger, R. J., & Palomo, T. (2011) · Neurotoxicity Research · doi:10.1007/s12640-010-9190-2 · Cited by 34
SKA2 regulated hyperactive secretory autophagy drives neuroinflammation-induced neurodegeneration
Hartmann, J., Bajaj, T., Otten, J., Klengel, C., Ebert, T., Gellner, A., Junglas, E., Hafner, K., Anderzhanova, E. A., Tang, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46953-x · Cited by 37
Zhong, L., Liu, H., Zhang, W., Liu, X., Jiang, B., Fei, H., & Sun, Z. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6860 · Cited by 34
Multifaceted Alzheimer’s Disease: Building a Roadmap for Advancement of Novel Therapies
Kaur, D., Behl, T., Sehgal, A., Singh, S., Sharma, N., & BUNGAU, S. G. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03415-w · Cited by 34
Jankovská, N., Olejár, T., & Matěj, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010007 · Cited by 35
Hadipour, M., Bahari, Z., Afarinesh, M. R., Jangravi, Z., Shirvani, H., & Meftahi, G. H. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13494 · Cited by 33
Gunnarsson, M. D., Lindau, M. P., Wall, A., Blennow, K., Darreh‐Shori, T., Basu, S., Nordberg, A. K., Larsson, A., Lannfelt, L., Basun, H., et al. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000281832 · Cited by 33
Gallo‐Payet, N. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00017 · Cited by 33
Relationship between long non-coding RNAs and Alzheimer’s disease: a systematic review
Chen, L., Guo, X., Li, Z., & He, Y. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.11.012 · Cited by 32
Dietary intake and cognitive function: evidence from the Bogalusa Heart Study
Fortune, N. C., Harville, E. W., Guralnik, J. M., Gustat, J., Chen, W., Qi, L., & Bazzano, L. (2019) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqz026 · Cited by 32
Frye, B. M., Craft, S., Latimer, C. S., Keene, C. D., Montine, T. J., Register, T. C., Orr, M. E., Kavanagh, K., Macauley, S. L., & Shively, C. A. (2021) · American Journal of Primatology · doi:10.1002/ajp.23260 · Cited by 34
Manipulation of the diet–microbiota–brain axis in Alzheimer’s disease
Lee, D. D., Lee, V. M. ‐., & Hur, S. K. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1042865 · Cited by 27
Invertebrate Models of Alzheimer's Disease
Mhatre, S. D., Paddock, B. E., Saunders, A. J., & Marenda, D. R. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121204 · Cited by 36
Quantitative neuropathological assessment to investigate cerebral multi-morbidity
Attems, J., Neltner, J. H., & Nelson, P. T. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0085-y · Cited by 32
Self-citationStojakovic, A., Chang, S.-Y., Nesbitt, J. J., Pichurin, N. P., Ostroot, M., Aikawa, T., Kanekiyo, T., & Trushina, E. V. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201015 · Cited by 31
Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials
Soejitno, A., Tjan, A., & Purwata, T. E. (2015) · CNS Drugs · doi:10.1007/s40263-015-0257-8 · Cited by 32
Shi, H., Mirzaei, N., Koronyo, Y., Davis, M. R., Robinson, E., Braun, G. M., Jallow, O., Rentsendorj, A., Ramanujan, V. K., Fert‐Bober, J., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02760-8 · Cited by 33
Inflammation Drives Alzheimer's Disease: Emphasis on 5-lipoxygenase Pathways
Siddiqui, A., Akhtar, S., Shah, Z., Othman, I., & Kumari, Y. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200924122732 · Cited by 30
de Sousa, A. A., Dames, B. A. R., Graff, E. C., Mohamedelhassan, R., Vassilopoulos, T., & Charvet, C. J. (2023) · Communications Biology · doi:10.1038/s42003-023-05034-3 · Cited by 36
Luna‐Muñoz, J., Charles, R., Claude, M., Flores-Rodríguez, P., Ávila, J., Sergio, R., de la Cruz, F., Mena, R., Meraz‐Ríos, M. A., & Florán, B. (2013) · InTech eBooks · doi:10.5772/54228 · Cited by 43
Wong, J. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000348406 · Cited by 30
Clinico-Neuropathological Findings in the Oldest Old from the Georgia Centenarian Study
Tanprasertsuk, J., Johnson, E. J., Johnson, M. A., Poon, L. W., Nelson, P. T., Davey, A., Martin, P., Barbey, A. K., Barger, K., Wang, X.-D., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181110 · Cited by 30
Self-citationAmyloid pathology in the progression to mild cognitive impairment
Insel, P. S., Hansson, O., Mackin, R. S., Weiner, M. W., & Mattsson, N. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.018 · Cited by 29
Gauthreaux, K. M., Mock, C., Teylan, M., Culhane, J. E., Chen, Y., Chan, K. C. G., Katsumata, Y., Nelson, P. T., & Kukull, W. A. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac093 · Cited by 29
Self-citationProtein aggregation and prionopathies
Renner, M. L., & Melki, R. (2014) · Pathologie Biologie · doi:10.1016/j.patbio.2014.01.003 · Cited by 31
Differential activation of the mTOR/autophagy pathway predicts cognitive performance in APP/PS1 mice
Vartak, R. S., Rodin, A., & Oddo, S. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.018 · Cited by 28
Xu, G. M., Fromholt, S., Chakrabarty, P., Zhu, F., Liu, X., Pace, M. C., Koh, J., Golde, T. E., Levites, Y., Lewis, J. M., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00911-y · Cited by 29
Regular Physical Exercise Modulates Iron Homeostasis in the 5xFAD Mouse Model of Alzheimer’s Disease
Belaya, I., Kucháriková, N., Górová, V., Kysenius, K., Hare, D. J., Crouch, P. J., Malm, T., Atalay, M., White, A. R., Liddell, J. R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168715 · Cited by 29
Alzheimer's disease‐like neuropathology in three species of oceanic dolphin
Vacher, M. C., Durrant, C. S., Rose, J. L., Hall, A. J., Spires‐Jones, T. L., Gunn‐Moore, F. J., & Dagleish, M. P. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15900 · Cited by 28
Borghys, H., Broeck, B. V., Dhuyvetter, D., Jacobs, T., Waepenaert, K. D., Erkens, T., Brooks, M., Thevarkunnel, S., & Araujo, J. A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160434 · Cited by 28
Brain regional synchronous activity predicts tauopathy in 3×TgAD mice
Liu, D., Lu, H., Stein, E. A., Zhou, Z., Yang, Y., & Mattson, M. P. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.016 · Cited by 28
Duggal, P., & Mehan, S. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190125 · Cited by 28
Li, J., Ebrahimi, A., & Ali, A. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105169 · Cited by 27
Medicinal Cannabis and Central Nervous System Disorders
Ortiz, Y. T., McMahon, L. R., & Wilkerson, J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.881810 · Cited by 29
Modulation of Gut Microbiota and Neuroprotective Effect of a Yeast-Enriched Beer
Cecarini, V., Gogoi, O., Bonfili, L., Veneruso, I., Pacinelli, G., Carlo, S. D., Benvenuti, F., D’Argenio, V., Angeletti, M., Cannella, N., et al. (2022) · Nutrients · doi:10.3390/nu14122380 · Cited by 27
Validation of a priori candidate Alzheimer’s disease SNPs with brain amyloid-beta deposition
Vacher, M., Porter, T., Villemagne, V. L., Milicic, L., Peretti, M., Fowler, C., Martins, R., Rainey-Smith, S., Ames, D., Masters, C. L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53604-5 · Cited by 26
Immunity impacts cognitive deficits across neurological disorders
Shaw, B. C., Anders, V., Tinkey, R. A., Habean, M. L., Brock, O. D., Frostino, B. J., & Williams, J. L. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15999 · Cited by 27
Dramatic impairment of prediction due to frontal lobe degeneration
Coppe, S., de Xivry, J. O., Yüksel, D., Ivanoiu, A., & Lefèvre, P. (2012) · Journal of Neurophysiology · doi:10.1152/jn.00582.2012 · Cited by 26
Metadata
- Authors
- Nelson, P. T., Braak, H., & Markesbery, W. R.
- Affiliations
- University of Kentucky HealthCare (US)
- University of Kentucky (US)
- Corresponding author
- Nelson, Peter T.
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01
- Volume
- 68
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- PMC
- PMC2692822
- OpenAlex
- W1985747467
- Cited by
- 643
- References
- 155
- Citations by year
- 2026: 21 · 2025: 43 · 2024: 48 · 2023: 46 · 2022: 33 · 2021: 45 · 2020: 44 · 2019: 33 · 2018: 32 · 2017: 32 · 2016: 37 · 2015: 32 · 2014: 35 · 2013: 42 · 2012: 41
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuropathology & Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (AG028 383)
- National Institute on Aging (P30AG028383)
- National Institute of Neurological Disorders and Stroke (R01NS061933, K08NS050110)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid plaques, neurofibrillary tangles, cognitive impairment, clinicopathological correlation, Alzheimer's disease diagnosis, Alzheimer disease pathogenesis, autopsy findings
- MeSH terms
- Alzheimer Disease, Cognition Disorders, Humans, Neurofibrillary Tangles, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
